SCHEMBL238073

SCHEMBL238073

Nc1c(CO)cnc2cc(-c3ccsc3)nn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KDM4E B2RXH2 3/20 0.48
FYN P06241 9/20 0.42
NPSR1 Q6W5P4 2/20 0.41
RXFP1 Q9HBX9 2/20 0.41
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
STAT1 P42224 1/20 0.40
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
DYRK3 O43781 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236328 0.84 NPC1 (0.52) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL2755214 0.81 NPC1 (0.61) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL2755166 0.81 NPC1 (0.51) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL238967 0.78 RAB9A (0.45) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL237831 0.78 RAB9A (0.67) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL2755225 0.75 NPC1 (0.55) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL238823 0.75 NPC1 (0.72) NPC1RAB9ASMN1; SMN2KDM4ERXFP1
SCHEMBL235072 0.74 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL235020 0.71 NPC1 (0.54) NPC1RAB9ASMN1; SMN2KDM4ENPSR1
SCHEMBL239025 0.69 FYN (0.38) NPC1RAB9ASMN1; SMN2KDM4EFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.